Want to see CNTA full AI Analyst Report?
CNTA Stock Chart & Stats
$39.66
-$0.91(-5.25%)
At close: 4:00 PM EST
$39.66
-$0.91(-5.25%)
Day’s Range― - ―
52-Week Range$12.39 - $40.26
Previous CloseN/A
Volume658.98K
Average Volume (3M)1.47M
Market Cap
$6.19B
Enterprise Value$6.11B
Total Cash (Recent Filing)$276.59M
Total Debt (Recent Filing)$7.37M
Price to Earnings (P/E)―
Beta1.17
Next Earnings
Aug 17, 2026EPS Estimate
-0.39Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.78
Shares Outstanding154,728,970
10 Day Avg. Volume2,085,497
30 Day Avg. Volume1,471,992
Financial Highlights & Ratios
PEG Ratio0.59
Price to Book (P/B)6.44
Price to Sales (P/S)226.28
P/FCF Ratio-17.48
Enterprise Value/Market Cap0.99
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-13.08K
Enterprise Value/Ebitda-23.47
Forecast
1Y Price Target
$43.50Price Target Upside9.68% Upside
Rating ConsensusHold
Number of Analyst Covering9
EPS Forecast (FY)-1.66
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Acquisition By Eli LillyThe completed acquisition materially reduces Centessa's standalone execution and financing risk by providing defined cash consideration and milestone-linked CVR upside. Integration into Lilly gives durable access to development, regulatory and commercialization resources that increase probability of advancing late-stage programs.
Low Leverage Balance SheetVery low debt provides structural financial flexibility and limits interest burden, helping preserve runway for clinical development and easing integration financing. This durable balance-sheet strength reduces bankruptcy risk and supports sustained R&D investment or transfer of programs within the acquirer.
Strategic Pipeline Fit In NeuroscienceCentessa's lead sleep-disorder assets align with Lilly's neuroscience strategy, creating durable commercial and development synergies. Access to Lilly's trial, regulatory and commercialization capabilities raises the structural odds of successful approvals and market launch versus remaining a small independent developer.
Bears Say
Zero TTM Revenue And Large LossesA development-stage profile with no recent product revenue and very large, recurring losses signals structural lack of operating cash generation. Without external funding or a strategic buyer, continued losses would erode equity and constrain long-term program funding and strategic optionality over the coming months.
Heavy Operating Cash BurnSustained negative operating and free cash flow create a persistent funding gap that pressures liquidity and forces reliance on financing or corporate transactions. This durable cash-burn profile increases execution risk for late-stage trials and makes program continuation contingent on external capital or integration support.
Leadership And Board TurnoverSudden departure of senior executives and directors poses structural continuity risk: loss of institutional knowledge and program stewardship can delay decisions, disrupt relationships with investigators and regulators, and complicate handoff of development programs during integration.
Centessa Pharmaceuticals News
CNTA FAQ
What was Centessa Pharmaceuticals Plc’s price range in the past 12 months?
Centessa Pharmaceuticals Plc lowest stock price was $12.39 and its highest was $40.26 in the past 12 months.
What is Centessa Pharmaceuticals Plc’s market cap?
Centessa Pharmaceuticals Plc’s market cap is $6.19B.
When is Centessa Pharmaceuticals Plc’s upcoming earnings report date?
Centessa Pharmaceuticals Plc’s upcoming earnings report date is Aug 17, 2026 which is in 47 days.
How were Centessa Pharmaceuticals Plc’s earnings last quarter?
Centessa Pharmaceuticals Plc released its earnings results on May 05, 2026. The company reported -$0.52 earnings per share for the quarter, missing the consensus estimate of -$0.405 by -$0.115.
Is Centessa Pharmaceuticals Plc overvalued?
According to Wall Street analysts Centessa Pharmaceuticals Plc’s price is currently Undervalued.
Does Centessa Pharmaceuticals Plc pay dividends?
Centessa Pharmaceuticals Plc pays a N/A dividend of $38 which represents an annual dividend yield of N/A. See more information on Centessa Pharmaceuticals Plc dividends here
What is Centessa Pharmaceuticals Plc’s EPS estimate?
Centessa Pharmaceuticals Plc’s EPS estimate is -0.39.
How many shares outstanding does Centessa Pharmaceuticals Plc have?
Centessa Pharmaceuticals Plc has 154,728,970 shares outstanding.
What happened to Centessa Pharmaceuticals Plc’s price movement after its last earnings report?
Centessa Pharmaceuticals Plc reported an EPS of -$0.52 in its last earnings report, missing expectations of -$0.405. Following the earnings report the stock price went down -0.076%.
Which hedge fund is a major shareholder of Centessa Pharmaceuticals Plc?
Currently, no hedge funds are holding shares in CNTA
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Centessa Pharmaceuticals Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
$43.50 (9.68% Upside)
$43.50 (9.68% Upside)
Blogger Sentiment
Bullish
CNTA Sentiment 70%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Increased
By 2.2M Shares
Last Quarter.
Last Quarter.
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
210.58%
12-Months-Change
Fundamentals
Return on Equity
-60.37%
Trailing 12-Months
Asset Growth
21.58%
Trailing 12-Months
Company Description
Centessa Pharmaceuticals Plc
Centessa Pharmaceuticals plc operates as a clinical-stage pharmaceutical enterprise focused on discovering, developing, and ultimately providing therapeutic solutions to patients. The company's most advanced product candidates include Lixivaptan, a small molecule inhibitor of the vasopressin V2 receptor, which is currently undergoing Phase III clinical evaluation for treating autosomal dominant polycystic kidney disease. Additionally, SerpinPC, an activated protein C inhibitor, is progressing through Phase IIa clinical development for the management of hemophilia A and B. Centessa's pipeline also features several emerging assets in the clinical proof-of-concept stage. These comprise LB101 (a PD-L1xCD47 LockBody) and LB201 (a PD-L1xCD3 LockBody), both engineered to selectively activate potent CD47 and CD3 effector functions while minimizing systemic side effects. Another molecule, ZF874, is a small molecule pharmacological chaperone in Phase I studies, designed to correct the misfolding of the Z variant of alpha-1-antitrypsin, thus addressing alpha-1-antitrypsin deficiency. Furthermore, MGX292, a recombinant modified BMP9 replacement protein, aims to rectify the deficient BMP9 signaling implicated in Pulmonary Arterial Hypertension. The company is also developing OX2R Agonists, which are selective orexin receptor 2 agonists (available as oral and intranasal formulations) intended to directly target the underlying pathophysiology of orexin neuron loss in Narcolepsy Type 1 by leveraging structural insights. Beyond these, Centessa is exploring further clinical proof-of-concept compounds. CBS001, an anti-LIGHT antibody, is being investigated for inflammatory and fibrotic diseases due to its preferential binding to the inflammatory membrane form of LIGHT. Lastly, CBS004 is a humanized monoclonal antibody specifically targeting BDCA2, a protein found exclusively on plasmacytoid dendritic cells, with potential utility in conditions such as systemic sclerosis, systemic lupus erythematosus, and other autoimmune disorders. Centessa Pharmaceuticals plc was established in 2020 and is headquartered in Altrincham, United Kingdom.
CNTA Stock 12 Month Forecast
Average Price Target
$43.50
▲(9.68% Upside)
Technical Analysis
Ownership Overview
0.17% Insiders
11.92% Mutual Funds
76.85% Other Institutional Investors
10.82% Public Companies and
Individual Investors